medullary thyroid cancer and glp-1 Receptor Agonists Risk, Rodent Data and FDA Warning, • In rodents, GLP-1 receptor agonists (GLP-1 RAs) stimulate thyroid C-cells, increasing the incidence of thyroid What are the risks and

National Library of Medicine Medical Subject Headings (MeSH)

6: Your prescriber may not be experienced with obesity medicine A 2025 cross-sectional study published in Obesity Medicine found that patients treated by an obesity specialist were 8 times more likely to remain on GLP-1 therapy than patients treated in general care settings (Liu et al., 2025)

If your symptoms are persistent, severe, or affecting your daily life, it is important to seek professional advice

This product is not recommended for pregnant or breastfeeding women, children, adolescents, diabetics, people with liver or heart problems, and those undergoing treatment with medication

H.MaddocksO